Conductus signs MRI pact with Siemens

Article

Improving the image quality of low-field MRI is the focus of anagreement announced last week between Conductus and Siemens. Underthe terms of the deal, Conductus, a Sunnyvale, CA, developer ofhigh-temperature superconducting technology, will work with

Improving the image quality of low-field MRI is the focus of anagreement announced last week between Conductus and Siemens. Underthe terms of the deal, Conductus, a Sunnyvale, CA, developer ofhigh-temperature superconducting technology, will work with theGerman vendor to design superconducting receiver subsystems forSiemens' Open 0.2-tesla MRI scanner. The subsystems will includesuperconducting receiver coils, associated electronics and cryogeniccooling. Conductus is one of several firms using high-temperaturesuperconducting technology to boost the signal-to-noise ratioof low-field images (SCAN 11/8/95).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.